JP2008538586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538586A5 JP2008538586A5 JP2008507992A JP2008507992A JP2008538586A5 JP 2008538586 A5 JP2008538586 A5 JP 2008538586A5 JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008507992 A JP2008507992 A JP 2008507992A JP 2008538586 A5 JP2008538586 A5 JP 2008538586A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- compound
- composition
- nac amide
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 94
- 150000001875 compounds Chemical class 0.000 claims 48
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 38
- 238000000034 method Methods 0.000 claims 30
- 230000008569 process Effects 0.000 claims 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 17
- 238000001914 filtration Methods 0.000 claims 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 15
- 238000001035 drying Methods 0.000 claims 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 10
- 238000002156 mixing Methods 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- 229910001868 water Inorganic materials 0.000 claims 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 8
- 150000008064 anhydrides Chemical class 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 8
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 6
- 239000003963 antioxidant agent Substances 0.000 claims 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 5
- 229910021529 ammonia Inorganic materials 0.000 claims 5
- 235000019270 ammonium chloride Nutrition 0.000 claims 5
- 230000003078 antioxidant effect Effects 0.000 claims 5
- -1 lithium aluminum hydride Chemical compound 0.000 claims 5
- 235000017281 sodium acetate Nutrition 0.000 claims 5
- 239000001632 sodium acetate Substances 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 159000000021 acetate salts Chemical class 0.000 claims 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 4
- 230000008859 change Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 4
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 claims 4
- 150000003573 thiols Chemical class 0.000 claims 4
- 108010024636 Glutathione Proteins 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000019838 Blood disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000008520 organization Effects 0.000 claims 2
- 238000012261 overproduction Methods 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001376 precipitating effect Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 230000008354 tissue degradation Effects 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- OYPOYMPGFACTLO-RGVONZFCSA-N (2r)-2-amino-3-[[(2r)-2,3-diamino-3-oxopropyl]disulfanyl]propanamide;dihydrochloride Chemical compound Cl.Cl.NC(=O)[C@@H](N)CSSC[C@H](N)C(N)=O OYPOYMPGFACTLO-RGVONZFCSA-N 0.000 claims 1
- PFRXZICTHLYYGK-UHFFFAOYSA-N 2,5,7-trimethoxynaphthalene-1,4-dione Chemical compound C1=C(OC)C=C2C(=O)C(OC)=CC(=O)C2=C1OC PFRXZICTHLYYGK-UHFFFAOYSA-N 0.000 claims 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- OYPOYMPGFACTLO-XWJKVJTJSA-N Cl.Cl.NC(=O)[C@H](N)CSSC[C@@H](N)C(N)=O Chemical compound Cl.Cl.NC(=O)[C@H](N)CSSC[C@@H](N)C(N)=O OYPOYMPGFACTLO-XWJKVJTJSA-N 0.000 claims 1
- 201000000054 Coronary Restenosis Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000004449 DNA Virus Infections Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 claims 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 238000000636 Northern blotting Methods 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000009341 RNA Virus Infections Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- 101710108790 Stromelysin-1 Proteins 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 239000002778 food additive Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000010166 immunofluorescence Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- UDHSAWHYRXHQJP-HNCPQSOCSA-N methyl (2R)-2-amino-3-phenylmethoxypropanoate hydrochloride Chemical compound Cl.COC(=O)[C@H](N)COCC1=CC=CC=C1 UDHSAWHYRXHQJP-HNCPQSOCSA-N 0.000 claims 1
- QVJDVOZRQMIIHP-PPHPATTJSA-N methyl (2r)-2-amino-3-benzylsulfanylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CSCC1=CC=CC=C1 QVJDVOZRQMIIHP-PPHPATTJSA-N 0.000 claims 1
- QVJDVOZRQMIIHP-HNCPQSOCSA-N methyl (2s)-2-amino-3-benzylsulfanylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CSCC1=CC=CC=C1 QVJDVOZRQMIIHP-HNCPQSOCSA-N 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 229920000962 poly(amidoamine) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 231100000133 toxic exposure Toxicity 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67356105P | 2005-04-21 | 2005-04-21 | |
| US70596705P | 2005-08-05 | 2005-08-05 | |
| PCT/US2006/015548 WO2006116353A2 (en) | 2005-04-21 | 2006-04-21 | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538586A JP2008538586A (ja) | 2008-10-30 |
| JP2008538586A5 true JP2008538586A5 (enExample) | 2009-07-09 |
Family
ID=37215387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507992A Pending JP2008538586A (ja) | 2005-04-21 | 2006-04-21 | 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド） |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20090234011A1 (enExample) |
| EP (1) | EP1877044A4 (enExample) |
| JP (1) | JP2008538586A (enExample) |
| KR (1) | KR20080028357A (enExample) |
| AU (1) | AU2006238888A1 (enExample) |
| CA (1) | CA2606053A1 (enExample) |
| IL (1) | IL186684A0 (enExample) |
| RU (1) | RU2007143040A (enExample) |
| WO (1) | WO2006116353A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| US12667548B2 (en) | 2014-11-07 | 2026-06-30 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312103T1 (de) | 1999-01-25 | 2005-12-15 | Nat Jewish Med & Res Center | Substituierte porphyrine und deren therapeutische verwendungen |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| CA2606053A1 (en) | 2005-04-21 | 2006-11-02 | Glenn Goldstein | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP2009525948A (ja) * | 2005-12-20 | 2009-07-16 | シラメッド・インコーポレーテッド | 高親油性スルフヒドリル化合物の製薬組成物及び使用方法 |
| US20100099762A1 (en) * | 2006-10-23 | 2010-04-22 | The Mental Health Research Institute Of Victoria | Combination therapy |
| US20080146579A1 (en) * | 2006-12-15 | 2008-06-19 | N.V. Nutricia | Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore |
| US9095578B2 (en) * | 2007-01-12 | 2015-08-04 | Cornell Research Foundation, Inc. | Adenylyl cyclases as novel targets for the treatment of infection by eukaryotic pathogens |
| CN101636157A (zh) * | 2007-01-12 | 2010-01-27 | 康乃尔研究基金会有限公司 | 作为抗菌干预的新型靶的腺苷酰环化酶 |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| CN102088965B (zh) * | 2008-05-13 | 2013-05-08 | 根梅迪卡治疗公司 | 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用 |
| DK2300003T3 (da) | 2008-05-23 | 2014-05-26 | Nat Jewish Health | Forbindelser til anvendelse i behandling af skade forbundet med eksponering for en alkylerende art |
| JP2012520342A (ja) * | 2009-03-16 | 2012-09-06 | ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ | 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート |
| CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
| JP2011088829A (ja) * | 2009-10-20 | 2011-05-06 | Chube Univ | 発癌毒性の評価方法及び発癌予防・治療剤 |
| TWI535440B (zh) | 2009-10-26 | 2016-06-01 | Ｌｇ生命科學有限公司 | 包括吲哚化合物之醫藥組成物 |
| US9433596B2 (en) | 2010-09-06 | 2016-09-06 | Snu R&Db Foundation | Pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder |
| FR2964967A1 (fr) | 2010-09-17 | 2012-03-23 | Exsymol Sa | Peptidomimetiques derives de la methionine et leur utilisation dans la protection des mitochondries des cellules cutanees |
| JP5854592B2 (ja) * | 2010-11-09 | 2016-02-09 | 丸善製薬株式会社 | 抗酸化剤及び抗炎症剤 |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| WO2012106654A1 (en) | 2011-02-04 | 2012-08-09 | Hough Ear Institute | Methods for treating brain injury |
| WO2013138744A1 (en) * | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| US9605047B2 (en) * | 2012-04-04 | 2017-03-28 | The Brigham And Womens's Hospital, Inc. | Compositions and methods for treating hypertension |
| WO2013163545A1 (en) * | 2012-04-26 | 2013-10-31 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| CA3078006C (en) * | 2012-07-10 | 2022-04-26 | Xpd Holdings, Llc | Stabilized multi-functional antioxidant compounds and methods of use |
| WO2015006569A2 (en) * | 2013-07-10 | 2015-01-15 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of penetrating head injury |
| EP3066089B1 (en) | 2013-11-08 | 2019-11-06 | Promentis Pharmaceuticals, Inc. | Substituted n-acetyl-l-cysteine derivatives and related compounds |
| US20150209310A1 (en) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or low impact brain trauma |
| WO2015112724A1 (en) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca for the treatment of chronic or acute cognitive dysfunction |
| WO2015134166A2 (en) * | 2014-02-12 | 2015-09-11 | Goldstein Glenn A | Use of n-acetylcysteine amide in the treatment of aquired immune deficiency syndrome and hiv infection |
| AU2015317877A1 (en) * | 2014-09-15 | 2017-05-04 | Sound Pharmaceuticals Incorporated | Methods and compositions for treating psychotic disorders |
| US12472157B2 (en) * | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| PE20180026A1 (es) | 2015-01-27 | 2018-01-09 | Florengale Llc | Composicion topica curativa |
| WO2016197089A1 (en) * | 2015-06-05 | 2016-12-08 | Goldstein Glenn A | Use of n-acetylcysteine amide in the treatment of acetaminophen overdose |
| JP7311267B2 (ja) * | 2016-01-11 | 2023-07-19 | エゲティス・セラピューティクス・アーベー | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| CN109562098B (zh) * | 2016-04-29 | 2023-04-21 | 奥菲瑞克斯股份有限公司 | 用于立即治疗膜翅目注毒和其他因组胺释放引起的病症的pla2抑制剂 |
| US12662449B2 (en) | 2017-09-20 | 2026-06-23 | Nacuity Pharmaceuticals, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20240368072A1 (en) * | 2017-09-20 | 2024-11-07 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
| CA3079196C (en) | 2017-09-20 | 2021-05-18 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US20240342118A1 (en) * | 2017-09-20 | 2024-10-17 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
| US20240217927A1 (en) * | 2017-11-09 | 2024-07-04 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| WO2019107913A1 (ko) * | 2017-11-28 | 2019-06-06 | 주식회사 셀투인 | 실시간 글루타치온 측정을 통한 치료용 세포의 품질 향상 방법 |
| CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| US11497758B2 (en) | 2018-11-15 | 2022-11-15 | Samuel L. Shepherd | Method of treating oxidative stress due to radiation exposure |
| AU2020206139A1 (en) | 2019-01-11 | 2021-07-29 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with N-acetylicysteine amide (NACA) or 2R,2R')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (diNACA) |
| WO2020146660A1 (en) * | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| CN109758581A (zh) * | 2019-02-14 | 2019-05-17 | 上海市东方医院（同济大学附属东方医院） | 一种抗氧化磁性氧化铁纳米颗粒及其制备方法 |
| EP3984993A4 (en) * | 2019-06-13 | 2023-07-19 | Shanghai Kechow Pharma, Inc. | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENTS |
| CA3165422A1 (en) | 2019-12-18 | 2021-06-24 | Neuronasal, Inc. | Methods of treating brain disorders |
| CN115151251A (zh) * | 2020-01-24 | 2022-10-04 | 纳崔泰制药有限公司 | 用于治疗氧化应激的疾病和损伤的前药 |
| WO2021252378A1 (en) * | 2020-06-08 | 2021-12-16 | Nacuity Pharmaceuticals, Inc. | Prevention or treatment of covid-19 |
| US20230263725A1 (en) * | 2020-07-09 | 2023-08-24 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
| IL300416A (en) * | 2020-08-06 | 2023-04-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Oleylcysteine amide or its derivatives and their uses |
| EP3960168A1 (en) * | 2020-08-28 | 2022-03-02 | Université de Genève | Compositions and methods comprising d-cysteine or a derivative thereof |
| CN112602724B (zh) * | 2020-12-21 | 2021-09-24 | 上海汉今医疗科技有限公司 | 一种感染性医疗废物消毒液及其制备方法 |
| AU2022204064A1 (en) | 2021-07-16 | 2023-02-02 | Samuel L. Shepherd | Method of treating oxidative stress due to radiation exposure |
| CN115449065B (zh) * | 2022-09-21 | 2023-09-22 | 中南大学湘雅医院 | 一种nac改性血液净化膜及其制备方法 |
| WO2026015776A1 (en) * | 2024-07-12 | 2026-01-15 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5691380A (en) | 1995-06-29 | 1997-11-25 | The Procter & Gamble Company | Stable n-acetylcysteine compositions and methods for treating human skin therewith |
| US5733535A (en) * | 1995-10-25 | 1998-03-31 | The Procter & Gamble Co. | Topical compositions containing N-acetylcysteine and odor masking materials |
| US5962421A (en) * | 1996-05-16 | 1999-10-05 | Zambon, S.A. | Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) * | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| US6719969B1 (en) | 1999-08-09 | 2004-04-13 | The Regents Of The University Of Michigan | Treatment of liver disease and injury with CXC chemokines |
| JP2002226457A (ja) * | 2001-02-02 | 2002-08-14 | Ajinomoto Co Inc | 新規シスチン誘導体及び炎症因子活性化抑制剤 |
| US6623754B2 (en) * | 2001-05-21 | 2003-09-23 | Noveon Ip Holdings Corp. | Dosage form of N-acetyl cysteine |
| AU2002323249A1 (en) * | 2001-08-16 | 2003-03-03 | Boyce Thompson Institute For Plant Research, Inc. | Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof |
| US20060211628A1 (en) * | 2002-08-02 | 2006-09-21 | Daphne Atlas | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| WO2004095926A2 (en) * | 2003-04-28 | 2004-11-11 | Monsanto Technology, Llc | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield |
| CA2606053A1 (en) | 2005-04-21 | 2006-11-02 | Glenn Goldstein | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| WO2006132712A2 (en) | 2005-04-21 | 2006-12-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for enhancing plant resistance and tolerance to environmental stress |
| EP1881840A4 (en) * | 2005-04-21 | 2009-08-05 | Glenn A Goldstein | N-ACETYLCYSTEINAMIDE (NAC-AMID) FOR THE TREATMENT OF OXIDATIVE STRESS IN CONNECTION WITH BARRENESS |
-
2006
- 2006-04-21 CA CA002606053A patent/CA2606053A1/en not_active Abandoned
- 2006-04-21 KR KR1020077027031A patent/KR20080028357A/ko not_active Withdrawn
- 2006-04-21 AU AU2006238888A patent/AU2006238888A1/en not_active Abandoned
- 2006-04-21 US US11/912,293 patent/US20090234011A1/en not_active Abandoned
- 2006-04-21 WO PCT/US2006/015548 patent/WO2006116353A2/en not_active Ceased
- 2006-04-21 EP EP06751310A patent/EP1877044A4/en not_active Withdrawn
- 2006-04-21 JP JP2008507992A patent/JP2008538586A/ja active Pending
- 2006-04-21 RU RU2007143040/15A patent/RU2007143040A/ru unknown
-
2007
- 2007-10-16 IL IL186684A patent/IL186684A0/en unknown
-
2010
- 2010-01-12 US US12/686,106 patent/US8354449B2/en not_active Expired - Fee Related
- 2010-02-17 US US12/707,092 patent/US8937099B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12667548B2 (en) | 2014-11-07 | 2026-06-30 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007143040A (ru) | Амид n-ацетилцистеина (амид nac) в лечении заболеваний и состояний, связанных с окислительным стрессом | |
| JP7101413B2 (ja) | 真菌感染症の治療方法 | |
| US9314532B2 (en) | Drug delivery vehicle | |
| EP2641605B1 (en) | Polymer derivative of cytidine metabolism antagonist | |
| CN104586859A (zh) | 喹硫平的氨基酸缀合物、其制备和使用方法 | |
| EP4245752A2 (en) | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses | |
| JP2011006428A5 (enExample) | ||
| TW200901964A (en) | Pharmaceutical formulations containing lipoic acid derivatives | |
| CN1708540A (zh) | 喜树碱的高分子衍生物 | |
| CA2983312A1 (en) | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof | |
| EP2623495B1 (en) | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate | |
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| AU2018392985A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
| CN116367837A (zh) | 抗病毒化合物的制剂 | |
| JP2023516628A (ja) | ヌクレオチド系化合物のコロナウイルス感染症の治療での使用 | |
| US20030232884A1 (en) | New pharmaceutical formulation | |
| WO2022022354A1 (zh) | 聚乙二醇偶联药物增效剂、其制备方法及用途 | |
| US8304565B2 (en) | PEG-lipid conjugates for liposomes and drug delivery | |
| CA2782224A1 (en) | Azilsartan organic amine salts, preparation method and use thereof | |
| JP2022120034A (ja) | 吸入粉末剤、その評価方法及びその用途 | |
| AU3943395A (en) | A chitosan polymer having a specific degree of acetylation | |
| US11524078B2 (en) | Water-soluble macromolecular derivative of Venetoclax | |
| KR102256453B1 (ko) | 소수성 약물 전달용 신규한 폴리머계 하이드로트로프 | |
| TW201113525A (en) | Methods for diagnosing diabetes and determining effectiveness of treatments | |
| EP3378494A1 (en) | Polymeric derivative of macrolide immunosuppressant |